XNCR
HEALTHCAREXencor Inc
$13.01+0.16 (+1.25%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving XNCR Today?
No stock-specific AI insight has been generated for XNCR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.92$18.69
$13.01
Fundamentals
Market Cap$964M
P/E Ratio—
EPS$-1.24
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.7%
Debt / Equity—
Trading
Volume819K
Avg Volume (10D)—
Shares Outstanding74.1M
XNCR News
21 articles- These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under ThreatYahoo Finance·May 8, 2026
- Xencor (NASDAQ: XNCR) posts deeper Q1 2026 loss amid royalty dispute and Zenas write-downStock Titan·May 7, 2026
- Xencor (XNCR) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance UK·May 7, 2026
- Xencor Reports First Quarter 2026 Financial ResultsYahoo Finance·May 6, 2026
- Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026Marketbeat·May 6, 2026
- Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDWYahoo Finance·May 4, 2026
- Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 1, 2026
- Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst callsYahoo Finance·Mar 24, 2026
- Xencor Announces Change to Ultomiris® Royalty Revenue ForecastYahoo Finance·Mar 4, 2026
- Xencor (XNCR) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Feb 26, 2026
- Xencor: Q4 Earnings SnapshotYahoo Finance·Feb 25, 2026
- Xencor Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Feb 25, 2026
- Xencor to Participate at Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
- What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma SectorYahoo Finance·Feb 8, 2026
- Xencor (XNCR): BofA Bullish on US Biopharmaceuticals CoverageYahoo Finance·Jan 30, 2026
- Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative?Yahoo Finance·Jan 20, 2026
- Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline MilestonesYahoo Finance·Jan 19, 2026
- [Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo Finance·Jan 14, 2026
- Xencor Highlights Corporate Priorities and 2026 Pipeline MilestonesYahoo Finance·Jan 8, 2026
- Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)Yahoo Finance·Dec 31, 2025
- Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ AntibodiesYahoo Finance·Dec 9, 2025
All 21 articles loaded
Price Data
Open$12.93
Previous Close$12.85
Day High$13.22
Day Low$12.72
52 Week High$18.69
52 Week Low$6.92
52-Week Range
$6.92$18.69
$13.01
Fundamentals
Market Cap$964M
P/E Ratio—
EPS$-1.24
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.7%
Debt / Equity—
Trading
Volume819K
Avg Volume (10D)—
Shares Outstanding74.1M
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—